
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The first study known to examine the relationship between the persistence of snoring and behavioral functioning in preschool-aged children found that persistent loud snoring is associated with increased rates of problem behaviors.






